**Question:** Which of the following statements about hydralazine is not true?

A. Hydralazine is a direct-acting vasodilator that inhibits vascular smooth muscle contraction.
B. Hydralazine reduces afterload in the treatment of hypertension.
C. Hydralazine is a calcium channel blocker.
D. Hydralazine is primarily used in the treatment of congestive heart failure.

**Core Concept:** Hydralazine is a vasodilator used to lower blood pressure. It works by inhibiting vascular smooth muscle contraction and reducing afterload, which means it decreases the amount of force required for the heart to pump blood. Hydralazine belongs to the class of medications known as direct-acting vasodilators, which means it acts directly on the blood vessels to widen them (dilate).

**Why the Correct Answer is Right:** Statement C ("Hydralazine is a calcium channel blocker") is not true, as hydralazine does not directly target calcium channels in the vascular smooth muscle cells. Instead, it inhibits the enzyme adenyl cyclase, which leads to a decrease in cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) production. This results in a reduction of vascular smooth muscle contraction and subsequent vasodilation.

**Why Each Wrong Option is Incorrect:**

A. While hydralazine does indeed reduce afterload, it is not primarily used in the treatment of congestive heart failure. Hydralazine is primarily used for the treatment of hypertension, especially in patients with black patients or those with severe hypertension that is resistant to other medications. It has a beneficial effect on the heart and kidneys by reducing afterload, which leads to improved cardiac output and renal blood flow.

B. Although hydralazine does lower blood pressure, it is not a calcium channel blocker. As explained earlier, hydralazine works by inhibiting adenyl cyclase, not modulating calcium channels.

D. The statement "Hydralazine is primarily used in the treatment of congestive heart failure" is incorrect. As mentioned, hydralazine is primarily used for hypertension, not heart failure. Heart failure patients may benefit from hydralazine's vasodilatory effects, but it is not the primary medication used for this indication. Other medications, such as ACE inhibitors or beta-blockers, are usually the first-line treatments for heart failure.

**Clinical Pearl:** Hydralazine is a valuable medication for treating hypertension, especially in black patients or those with resistant hypertension. Its vasodilatory effects on afterload help to improve cardiac output and renal blood flow. However, hydralazine should not be considered as the first-choice medication for congestive heart failure treatment, as other medications like ACE inhibitors or beta-blockers are typically preferred.